Quantcast

Latest Multiple Myeloma Research Foundation Stories

2008-08-13 09:01:15

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a four-drug combination study with REVLIMID(R) (lenalidomide), VELCADE(R) (bortezomib) for Injection, DOXIL(R) (doxorubicin HCl liposome injection) and dexamethasone for the treatment of multiple myeloma in patients who are previously untreated. The University of Michigan, one of fifteen MMRC member institutions, will evaluate the safety and efficacy of the drug combination in patients who have not received...

2008-07-18 15:00:57

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a Phase I/II study of elotuzumab (also known as Huluc63), a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in combination with VELCADE(R) (bortezomib) for Injection for the treatment of relapsed multiple myeloma. This study, sponsored by PDL BioPharma, Inc., and conducted at the following MMRC Member Institutions: the University of Michigan, Dana-Farber Cancer Institute, University...

2008-06-27 15:03:00

The Multiple Myeloma Research Consortium (MMRC) today announced the addition of two Member Institutions. The new institutions, Indiana University Simon Cancer Center in Indianapolis and the University of California, San Francisco (UCSF), were selected following a highly competitive Request for Application (RFA) process. The MMRC's current 13 Member Institutions are among the world's most prestigious academic research institutions. Indiana University and UCSF were selected to join the...

2008-06-24 02:30:28

New Indication Provides Treatment-Free Interval As an Option Media: International Myeloma Foundation Peggy Frank, 818-735-3591 Logo: http://myeloma.org/ The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today applauded the decision by the US Food and Drug Administration (FDA) to expand the benefits of VELCADE(R) (bortezomib) for injection to a wider range of...

2008-06-17 03:00:38

Celgene Corporation David Gryska, 908-673-9059 Sr. Vice President and Chief Financial Officer or Brian P. Gill, 908-673-9530 Vice President, Corporate Communications Data from the ECOG E4A03 and SWOG 0232 studies were reported at a Satellite Symposium and showed that newly diagnosed multiple myeloma patients who are eligible for a transplant, obtain better outcomes when treated with REVLIMID (lenalidomide) plus dexamethasone. The data were presented by Dr A. Stewart, from the Mayo...

2008-06-14 12:00:24

Celgene International Sarl (Nasdaq:CELG) announced that data presented today at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark found that patients previously treated for multiple myeloma receiving REVLIMID (lenalidomide) in combination with dexamethasone experienced a significant survival gain regardless of the number of prior therapies they had received. The results showed that not only was the use of REVLIMID and dexamethasone associated with a...

2005-06-02 23:26:36

BOSTON - A novel strategy devised by Dana-Farber Cancer Institute scientists has proved highly effective in killing drug-resistant multiple myeloma cells in the laboratory and could open a new form of attack on the deadly blood cancer, they report. Highly encouraged by the findings, the researchers hope to move rapidly to clinical trials of the therapy, a combination of the drug Velcade and an experimental compound that was designed by researchers at the Broad Institute of Massachusetts...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related